+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunoglobulin Product Market - Global Forecast 2026-2032- Product Image
Immunoglobulin Product Market - Global Forecast 2026-2032- Product Image
Sale

Immunoglobulin Product Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904902
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Immunoglobulin Product Market is projected to reach USD 24.00 Billion in 2026. It is expected to continue growing at a CAGR of 13.04%, reaching USD 50.29 Billion by 2032.

Immunoglobulin products are plasma-derived biologic therapies used to replace or modulate antibodies in patients with immune-mediated and infection-risk conditions. The category includes intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and specialty formulations used across primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, immune thrombocytopenia, multifocal motor neuropathy, Kawasaki disease, multifocal motor neuropathy, and selected secondary immunodeficiency settings.

The immunoglobulin product market is shaped by rising diagnosis of immune disorders, broader use in neurology and hematology, and persistent supply constraints tied to human plasma collection, fractionation capacity, viral safety testing, regulatory release, and cold-chain distribution. For industry leaders, competitive advantage depends on secure plasma access, reliable manufacturing quality, patient-friendly administration options, traceability, and payer-supported evidence of clinical value.

Transformative Shifts in the Immunoglobulin Landscape

The immunoglobulin product landscape is moving from hospital-centered IVIG administration toward more flexible care models that include home infusion and SCIG self-administration. This shift is supported by clinical practice patterns that favor reduced infusion-center burden, stable serum IgG exposure, fewer systemic infusion-related reactions for some patients, and improved patient autonomy where medically appropriate.

At the same time, supply resilience has become a strategic priority. Because immunoglobulin products depend on donated human plasma and complex fractionation, short-term demand shocks cannot be solved instantly. Manufacturers and healthcare systems are investing in donor-center networks, yield optimization, manufacturing redundancy, validated quality systems, improved inventory planning, and appropriate-use protocols to protect continuity of therapy for patients who rely on these essential biologics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the full immunoglobulin product value chain. In plasma operations, AI-enabled analytics can improve donor scheduling, forecast collection volumes, identify operational bottlenecks, support compliance monitoring, and strengthen traceability across regulated donation networks.

In manufacturing and commercial operations, machine learning can support batch-trend analysis, deviation detection, demand forecasting, pharmacovigilance signal management, inventory allocation, and cold-chain risk prediction. The cumulative impact is not replacement of regulatory science or clinician judgment, but faster and more consistent decision support in a market where product availability, safety, traceability, and appropriate allocation are critical.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America remains a central hub for immunoglobulin product demand and plasma supply, led by the United States with extensive plasma collection infrastructure, advanced specialty care, and strong utilization in immunology, neurology, and hematology. Canada has a more centralized blood and plasma governance model, making supply planning, national coordination, domestic collection strategy, and import dependence important policy considerations.

Europe is defined by mature regulatory oversight, broad clinical adoption, national reimbursement systems, and continuing policy focus on plasma self-sufficiency and appropriate use of IVIG and SCIG. Asia-Pacific is expanding as diagnosis rates improve in China, India, Japan, South Korea, and Australia, although access varies by reimbursement maturity, local fractionation capacity, specialist availability, regulatory pathways, and urban-rural healthcare differences.

Latin America shows growing demand in Brazil and Mexico, but availability can be uneven because of budget constraints, tender cycles, distribution complexity, and reliance on imported plasma derivatives. The Middle East, especially GCC markets, benefits from investment in tertiary care and specialty hospitals, while Africa faces the largest access gaps due to limited plasma infrastructure, affordability barriers, constrained diagnostic capacity, and uneven cold-chain reach.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN markets are gaining relevance as immunology and neurology services expand, but product access differs sharply between higher-income health systems and markets with limited reimbursement, specialist coverage, and plasma-derived therapy budgets. The GCC is characterized by strong hospital investment, demand for advanced biologics, and centralized procurement that can accelerate access when supply contracts, registration pathways, and logistics capacity are secure.

The European Union remains a major regulatory and demand center, with strict quality standards, pharmacovigilance requirements, national reimbursement assessment, and policy focus on plasma sufficiency. BRICS countries represent a strategically important opportunity because of large populations, rising diagnosis, and investments in domestic biomanufacturing and healthcare capacity, although pricing, reimbursement, import reliance, and access barriers remain significant.

G7 markets account for substantial global immunoglobulin consumption because they combine advanced diagnostics, established clinical guidelines, broad specialist networks, and payer coverage for approved indications. NATO countries overlap substantially with high-income systems in North America and Europe, where supply security, strategic reserves, cross-border logistics, and resilient healthcare infrastructure are increasingly important for plasma-derived medicinal products.

Key Country Insights: U.S., Canada, Mexico, Brazil, Europe, China, India, Japan, Australia & South Korea

The United States is the most influential immunoglobulin product market because of its large diagnosed patient base, strong specialty infusion ecosystem, broad payer channels, and unmatched plasma collection scale. Canada emphasizes managed access and national blood-system coordination, while Mexico is expanding specialty care but remains sensitive to pricing, reimbursement gaps, product registration, and public procurement dynamics.

Brazil leads Latin American demand, supported by a large healthcare system and growing biologics use, while the United Kingdom, Germany, France, Italy, and Spain represent established European markets with guideline-driven utilization, pharmacovigilance expectations, and payer scrutiny. Russia has demand for plasma-derived therapies but faces supply-chain, currency, procurement, and geopolitical constraints that can affect access and continuity.

China and India offer long-term growth potential as diagnosis improves, hospital capacity expands, and healthcare coverage broadens, but access remains uneven across regions and income segments. Japan, Australia, and South Korea are mature Asia-Pacific markets with high regulatory standards, strong specialty care, established blood-system oversight, and increasing emphasis on patient-centered administration models such as SCIG and home-based care where clinically suitable.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize plasma supply security by diversifying donor-center networks, strengthening long-term collection partnerships, improving donor retention, and investing in fractionation capacity and manufacturing redundancy. In a constrained market, continuity of supply is both a core commercial differentiator and a patient-safety obligation.

Organizations should also expand evidence generation for approved indications, real-world outcomes, safety monitoring, dosing patterns, switching practices, and health-economic value. Patient support programs, home-infusion partnerships, SCIG education, digital adherence tools, and clinician-facing appropriate-use resources can improve persistence while supporting payers that require proof of responsible utilization.

To improve resilience, leaders should integrate AI-enabled demand planning, cold-chain visibility, pharmacovigilance analytics, and quality-management systems without compromising regulatory oversight. Regional strategies should align product availability with reimbursement rules, tender cycles, clinical guideline adoption, and the documented needs of immunology, neurology, and hematology specialists.

Research Methodology

This executive summary is structured using a secondary research methodology grounded in publicly available regulatory, clinical, and industry intelligence sources. Relevant inputs include prescribing information, regulatory guidance from agencies such as the FDA and EMA, clinical guidelines, blood and plasma policy publications, healthcare access reports, pharmacovigilance references, and peer-reviewed literature on immunoglobulin use.

Insights were synthesized through comparative regional analysis, product-category assessment, demand-driver evaluation, supply-chain review, and healthcare access interpretation. The methodology emphasizes verified industry facts, avoids unsupported projections, and focuses on commercially actionable themes affecting immunoglobulin product access, manufacturing, reimbursement, quality assurance, and adoption.

Conclusion

Immunoglobulin products will remain essential therapies in immunology, neurology, hematology, and inflammatory disease management. Demand is supported by better diagnosis, established clinical indications, expanding care pathways, and patient preference for flexible administration, while supply remains limited by the realities of plasma collection, fractionation timelines, quality testing, and biologics manufacturing.

Market leaders that combine secure plasma sourcing, disciplined quality systems, AI-enabled operations, patient-centered commercialization, and robust evidence generation will be best positioned to compete. The future of the immunoglobulin product market will be defined by reliability, clinical evidence, equitable access, and resilient global supply chains.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Immunoglobulin Product Market, by Product Type
7.1. Introduction
7.2. Hyperimmune Globulin
7.3. Standard Immunoglobulin
8. Immunoglobulin Product Market, by Source
8.1. Introduction
8.2. Pooled Human Plasma
8.3. Recombinant
9. Immunoglobulin Product Market, by Route Of Administration
9.1. Introduction
9.2. Intramuscular
9.3. Intravenous
9.4. Subcutaneous
10. Immunoglobulin Product Market, by Application
10.1. Introduction
10.2. Hematological Disorders
10.2.1. Hemolytic Anemia
10.2.2. Idiopathic Thrombocytopenic Purpura
10.3. Infectious Diseases
10.3.1. Hepatitis A
10.3.2. Rubella
10.3.3. Varicella
10.4. Neurological Disorders
10.4.1. Chronic Inflammatory Demyelinating Polyneuropathy
10.4.2. Guillain-Barre Syndrome
10.4.3. Myasthenia Gravis
10.5. Primary Immune Deficiency
10.5.1. Common Variable Immunodeficiency
10.5.2. Severe Combined Immunodeficiency
10.5.3. X-Linked Agammaglobulinemia
11. Immunoglobulin Product Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Immunoglobulin Product Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Immunoglobulin Product Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. ADMA Biologics, Inc.
15.2. Bharat Serums and Vaccines Limited
15.3. Bio Products Laboratory Limited
15.4. Biotest AG
15.5. China Biologic Products Holdings, Inc.
15.6. CSL Limited
15.7. Emergent BioSolutions Inc.
15.8. GC Biopharma Corp.
15.9. Green Cross Corporation
15.10. Grifols, S.A.
15.11. Hualan Biological Engineering Inc.
15.12. Intas Pharmaceuticals Ltd.
15.13. Kamada Ltd.
15.14. Kedrion S.p.A.
15.15. LFB S.A.
15.16. Octapharma AG
15.17. PharmaSwiss SA
15.18. Prothya Biosolutions B.V.
15.19. Reliance Life Sciences Pvt. Ltd.
15.20. Sanquin Plasma Products B.V.
15.21. Shanghai RAAS Blood Products Co., Ltd.
15.22. SK Plasma Co., Ltd.
15.23. Takeda Pharmaceutical Company Limited
16. Key Experts
List of Figures
FIGURE 1. Global Immunoglobulin Product Market, Years Considered for the Study
FIGURE 2. Global Immunoglobulin Product Market, Research Design
FIGURE 3. Global Immunoglobulin Product Market, Research Framework
FIGURE 4. Global Immunoglobulin Product Market, Data Triangulation
FIGURE 5. Global Immunoglobulin Product Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Immunoglobulin Product Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Immunoglobulin Product Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Immunoglobulin Product Market Size, by Source, 2025 vs 2032 (%)
FIGURE 9. Global Immunoglobulin Product Market Size, by Source, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Immunoglobulin Product Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Immunoglobulin Product Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Immunoglobulin Product Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global Immunoglobulin Product Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Immunoglobulin Product Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Immunoglobulin Product Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Immunoglobulin Product Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Immunoglobulin Product Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Immunoglobulin Product Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Immunoglobulin Product Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Immunoglobulin Product Market Segmentation & Coverage
TABLE 2. Global Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 3. Global Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Hyperimmune Globulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Hyperimmune Globulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Hyperimmune Globulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Standard Immunoglobulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Standard Immunoglobulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Standard Immunoglobulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 11. Global Pooled Human Plasma Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Pooled Human Plasma Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Pooled Human Plasma Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 18. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 28. Global Hematological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Hematological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Hematological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Hemolytic Anemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Hemolytic Anemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Hemolytic Anemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Idiopathic Thrombocytopenic Purpura Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Idiopathic Thrombocytopenic Purpura Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Idiopathic Thrombocytopenic Purpura Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Hepatitis A Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Hepatitis A Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Hepatitis A Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Rubella Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Rubella Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Rubella Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Varicella Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Varicella Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Varicella Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Chronic Inflammatory Demyelinating Polyneuropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Chronic Inflammatory Demyelinating Polyneuropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Chronic Inflammatory Demyelinating Polyneuropathy Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Guillain-Barre Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Guillain-Barre Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Guillain-Barre Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Myasthenia Gravis Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Myasthenia Gravis Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Myasthenia Gravis Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Primary Immune Deficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Primary Immune Deficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Primary Immune Deficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Common Variable Immunodeficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Common Variable Immunodeficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Common Variable Immunodeficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Severe Combined Immunodeficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Severe Combined Immunodeficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Severe Combined Immunodeficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global X-Linked Agammaglobulinemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global X-Linked Agammaglobulinemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global X-Linked Agammaglobulinemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Immunoglobulin Product Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Immunoglobulin Product Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 83. North America Immunoglobulin Product Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. North America Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 85. North America Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 86. North America Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 87. North America Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 88. North America Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 89. North America Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 90. North America Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 91. North America Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 92. Latin America Immunoglobulin Product Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Latin America Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 94. Latin America Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 95. Latin America Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 96. Latin America Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 97. Latin America Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 98. Latin America Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 99. Latin America Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 100. Latin America Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 101. Europe Immunoglobulin Product Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Europe Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 103. Europe Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 104. Europe Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 105. Europe Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 106. Europe Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 107. Europe Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 108. Europe Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 109. Europe Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 110. Middle East Immunoglobulin Product Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Middle East Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 112. Middle East Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 113. Middle East Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 114. Middle East Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 115. Middle East Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 116. Middle East Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 117. Middle East Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 118. Middle East Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 119. Africa Immunoglobulin Product Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Africa Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 121. Africa Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 122. Africa Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 123. Africa Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 124. Africa Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 125. Africa Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 126. Africa Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 127. Africa Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 128. Global Immunoglobulin Product Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. ASEAN Immunoglobulin Product Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. ASEAN Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 131. ASEAN Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 132. ASEAN Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 133. ASEAN Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 134. ASEAN Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 135. ASEAN Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 136. ASEAN Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 137. ASEAN Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 138. GCC Immunoglobulin Product Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. GCC Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 140. GCC Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 141. GCC Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 142. GCC Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 143. GCC Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 144. GCC Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 145. GCC Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 146. GCC Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 147. European Union Immunoglobulin Product Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. European Union Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 149. European Union Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 150. European Union Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 151. European Union Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 152. European Union Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 153. European Union Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 154. European Union Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 155. European Union Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 156. BRICS Immunoglobulin Product Market Size, by Group, 2017-2032 (USD Million)
TABLE 157. BRICS Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 158. BRICS Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 159. BRICS Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 160. BRICS Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. BRICS Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 162. BRICS Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 163. BRICS Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 164. BRICS Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 165. G7 Immunoglobulin Product Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. G7 Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 167. G7 Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 168. G7 Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 169. G7 Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 170. G7 Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 171. G7 Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 172. G7 Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 173. G7 Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 174. NATO Immunoglobulin Product Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. NATO Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 176. NATO Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 177. NATO Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 178. NATO Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 179. NATO Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 180. NATO Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 181. NATO Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 182. NATO Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 183. Global Immunoglobulin Product Market Size, by Country, 2017-2032 (USD Million)
TABLE 184. United States Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 185. United States Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 186. United States Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 187. United States Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 188. United States Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 189. United States Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 190. United States Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 191. United States Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 192. United States Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 193. Canada Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 194. Canada Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 195. Canada Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 196. Canada Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 197. Canada Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 198. Canada Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 199. Canada Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 200. Canada Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 201. Canada Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 202. Mexico Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 203. Mexico Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 204. Mexico Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 205. Mexico Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 206. Mexico Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 207. Mexico Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 208. Mexico Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 209. Mexico Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 210. Mexico Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 211. Brazil Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 212. Brazil Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 213. Brazil Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 214. Brazil Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 215. Brazil Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 216. Brazil Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 217. Brazil Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 218. Brazil Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 219. Brazil Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 220. United Kingdom Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 221. United Kingdom Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 222. United Kingdom Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 223. United Kingdom Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 224. United Kingdom Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 225. United Kingdom Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 226. United Kingdom Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 227. United Kingdom Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 228. United Kingdom Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 229. Germany Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 230. Germany Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 231. Germany Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 232. Germany Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 233. Germany Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 234. Germany Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 235. Germany Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 236. Germany Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 237. Germany Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 238. France Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 239. France Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 240. France Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 241. France Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 242. France Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 243. France Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 244. France Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 245. France Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 246. France Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 247. Russia Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 248. Russia Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 249. Russia Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 250. Russia Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 251. Russia Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 252. Russia Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 253. Russia Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 254. Russia Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 255. Russia Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 256. Italy Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 257. Italy Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 258. Italy Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 259. Italy Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 260. Italy Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 261. Italy Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 262. Italy Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 263. Italy Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 264. Italy Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 265. Spain Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 266. Spain Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 267. Spain Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 268. Spain Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 269. Spain Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 270. Spain Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 271. Spain Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 272. Spain Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 273. Spain Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 274. China Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 275. China Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 276. China Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 277. China Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 278. China Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 279. China Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 280. China Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 281. China Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 282. China Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 283. India Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 284. India Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 285. India Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 286. India Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 287. India Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 288. India Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 289. India Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 290. India Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 291. India Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 292. Japan Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 293. Japan Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 294. Japan Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 295. Japan Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 296. Japan Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 297. Japan Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 298. Japan Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 299. Japan Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 300. Japan Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 301. Australia Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 302. Australia Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 303. Australia Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 304. Australia Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 305. Australia Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 306. Australia Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 307. Australia Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 308. Australia Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 309. Australia Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 310. South Korea Immunoglobulin Product Market Size, 2017-2032 (USD Million)
TABLE 311. South Korea Immunoglobulin Product Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 312. South Korea Immunoglobulin Product Market Size, by Source, 2017-2032 (USD Million)
TABLE 313. South Korea Immunoglobulin Product Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 314. South Korea Immunoglobulin Product Market Size, by Application, 2017-2032 (USD Million)
TABLE 315. South Korea Immunoglobulin Product Market Size, by Hematological Disorders, 2017-2032 (USD Million)
TABLE 316. South Korea Immunoglobulin Product Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 317. South Korea Immunoglobulin Product Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 318. South Korea Immunoglobulin Product Market Size, by Primary Immune Deficiency, 2017-2032 (USD Million)
TABLE 319. Global Immunoglobulin Product Market Share, by Key Player, 2025
TABLE 320. Global Immunoglobulin Product Market, Key Experts

Companies Mentioned

  • ADMA Biologics, Inc.
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory Limited
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GC Biopharma Corp.
  • Green Cross Corporation
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kamada Ltd.
  • Kedrion S.p.A.
  • LFB S.A.
  • Octapharma AG
  • PharmaSwiss SA
  • Prothya Biosolutions B.V.
  • Reliance Life Sciences Pvt. Ltd.
  • Sanquin Plasma Products B.V.
  • Shanghai RAAS Blood Products Co., Ltd.
  • SK Plasma Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages181
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 24 Billion
Forecasted Market Value ( USD ) by 2032 $ 50.29 Billion
Compound Annual Growth Rate13.0%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Intravenous Immunoglobulin Market - Global Forecast 2026-2032 - Product Image

Intravenous Immunoglobulin Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Subcutaneous Immunoglobulin Market - Global Forecast 2026-2032 - Product Image

Subcutaneous Immunoglobulin Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Subcutaneous Immunoglobulin - Global Strategic Business Report - Product Image

Subcutaneous Immunoglobulin - Global Strategic Business Report

  • Report
  • 226 Pages
  • Global
From
Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Immunoglobulin Market Size, Share, Trends and Forecast by Product, Application, Mode of Delivery, and Region, 2026-2034 - Product Image

Immunoglobulin Market Size, Share, Trends and Forecast by Product, Application, Mode of Delivery, and Region, 2026-2034

  • Report
  • 136 Pages
  • Global
From

About the Immunoglobulin Market

The Immunoglobulin market is a segment of the Immune Disorders Drugs market, which focuses on treatments for conditions related to the immune system. Immunoglobulin (Ig) is a type of protein found in the blood that helps fight infection and disease. It is used to treat a variety of immune-related conditions, including autoimmune diseases, allergies, and infections. Immunoglobulin therapies are typically administered intravenously or subcutaneously, and can be used to replace or supplement the body's natural Ig production. The Immunoglobulin market is highly competitive, with a number of companies offering a range of products. These products vary in terms of dosage, delivery method, and cost. Companies in the market are focused on developing new therapies and improving existing ones, as well as expanding their product portfolios. Some of the major companies in the Immunoglobulin market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.